|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sequist LV, Yang JC, Yamamoto N, O'Byrne
K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, et al:
Phase Ⅲ study of afatinib or cisplatin plus pemetrexed in patients
with metastatic lung adenocarcinoma with EGFR mutations. J Clin
Oncol. 31:3327–3334. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Shaw AT, Ou SH, Bang YJ, Camidge DR,
Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa
DB, et al: Crizotinib in ROS1-rearranged non-small-cell lung
cancer. N Engl J Med. 371:1963–1971. 2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Planchard D, Smit EF, Groen HJM, Mazieres
J, Besse B, Helland Å, Giannone V, D'Amelio AM Jr, Zhang P,
Mookerjee B and Johnson BE: Dabrafenib plus trametinib in patients
with previously treated BRAF (V600E)-mutant metastatic non-small
cell lung cancer: An open-label, multicentre phase 2 trial. Lancet
Oncol. 18:1307–1316. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Paik PK, Felip E, Veillon R, Sakai H,
Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van
Meerbeeck J, et al: Tepotinib in non-small-cell lung cancer with
MET exon 14 skipping mutations. N Engl J Med. 383:931–943.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wolf J, Seto T, Han JY, Reguart N, Garon
EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, et al:
Capmatinib (INC280) in METΔex14-mutated advanced non-small
cell lung cancer (NSCLC): Efficacy data from the phase Ⅱ GEOMETRY
mono-1 study. J Clin Oncol. 37 (Suppl 15)(9004)2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus Chemotherapy for PD-L1-Positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833.
2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092.
2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Paz-Ares L, Luft A, Vicente D, Tafreshi A,
Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, et
al: Pembrolizumab plus chemotherapy for squamous non-small-cell
lung cancer. N Engl J Med. 379:2040–2051. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
National Comprehensive Cancer Network
(NCCN): Clinical Practice Guidelines in Oncology (NCCN
Guidelines®). Non-Small Cell Lung Cancer. Version
5.2021. NCCN, Plymouth Meeting, PA, 2021. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
|
|
14
|
Nakamura Y: Biomarkers for immune
checkpoint inhibitor-mediated tumor response and adverse events.
Front Med (Lausanne). 6(119)2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Schildhaus HU: Predictive value of PD-L1
diagnostics. Pathologe. 39:498–519. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lagos GG, Izar B and Rizvi NA: Beyond
tumor PD-L1: Beyond tumor PD-L1: Emerging genomic biomarkers for
checkpoint inhibitor immunotherapy. Am Soc Clin Oncol Educ Book.
40:1–11. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Chindaprasirt J: Sarcopenia in cancer
patients. Asian Pac J Cancer Prev. 16:8075–8077. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Roch B, Coffy A, Jean-Baptiste S, Palaysi
E, Daures JP, Pujol JL and Bommart S: Cachexia-sarcopenia as a
determinant of disease control rate and survival in non-small lung
cancer patients receiving immune-checkpoint inhibitors. Lung
Cancer. 143:19–26. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nishioka N, Uchino J, Hirai S, Katayama Y,
Yoshimura A, Okura N, Tanimura K, Harita S, Imabayashi T, Chihara
Y, et al: Association of sarcopenia with and efficacy of
anti-PD-1/PD-L1 therapy in non-small-cell lung cancer. J Clin Med.
8(450)2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
U.S. Department of Health and Human
Services, National Institutes of Health National Cancer Institute:
Common Terminology Criteria for Adverse Events (CTCAE). Version
4.0. https://www.eortc.be/services/doc/ctc/. Accessed
September 1, 2018.
|
|
23
|
Shiroyama T, Nagatomo I, Koyama S, Hirata
H, Nishida S, Miyake K, Fukushima K, Shirai Y, Mitsui Y, Takata S,
et al: Impact of sarcopenia in patients with advanced non-small
cell lung cancer treated with PD-1 inhibitors: A preliminary
retrospective study. Sci Rep. 9(2447)2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Peixoto da Silva S, Santos JMO, Costa E
Silva MP, Gil da Costa RM and Medeiros R: Cancer cachexia and its
pathophysiology: Links with sarcopenia, anorexia and asthenia. J
Cachexia Sarcopenia Muscle. 11:619–635. 2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Sanders KJ, Hendriks LE, Troost EG,
Bootsma GP, Houben RM, Schols AM and Dingemans AM: Early weight
loss during chemoradiotherapy has a detrimental impact on outcome
in NSCLC. J Thorac Oncol. 11:873–879. 2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Ross PJ, Ashley S, Norton A, Priest K,
Waters JS, Eisen T, Smith IE and O'Brien ME: Do patients with
weight loss have a worse outcome when undergoing chemotherapy for
lung cancers? Br J Cancer. 90:1905–1911. 2004.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Petruzzelli M and Wagner EF: Mechanisms of
metabolic dysfunction in cancer-associated cachexia. Genes Dev.
30:489–501. 2016.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Flint TR, Janowitz T, Connell CM, Roberts
EW, Denton AE, Coll AP, Jodrell DI and Fearon DT: Tumor-Induced
IL-6 reprograms host metabolism to suppress anti-tumor immunity.
Cell Metab. 24:672–684. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Katakami N, Uchino J, Yokoyama T, Naito T,
Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, et al:
Anamorelin (ONO-7643) for the treatment of patients with non-small
cell lung cancer and cachexia: Results from a randomized,
double-blind, placebo-controlled, multicenter study of Japanese
patients (ONO-7643-04). Cancer. 124:606–616. 2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Osorio JC, Ni A, Chaft JE, Pollina R,
Kasler MK, Stephens D, Rodriguez C, Cambridge L, Rizvi H, Wolchok
JD, et al: Antibody-mediated thyroid dysfunction during T-cell
checkpoint blockade in patients with non-small-cell lung cancer.
Ann Oncol. 28:583–589. 2017.PubMed/NCBI View Article : Google Scholar
|
